Trials / Unknown
UnknownNCT05802420
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before first-line chemotherapy initiation and at the first imaging assessment after chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Later-line therapy | Another chemotherapy regimen, targeted therapy, or immunotherapy |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2023-04-06
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05802420. Inclusion in this directory is not an endorsement.